Navigation Links
YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
Date:9/17/2009

is and the ongoing palliative NSCLC randomized trial. In this trial, as with the others being conducted by YM, extensive samples are being collected and stored in anticipation of a comprehensive program of translational analysis," said Dr. Leonardo Viana Nicacio, YM's Director of Clinical Affairs.

Nimotuzumab is reported to have been has been administered to more than 5,000 patients worldwide and is currently in 32 trials internationally of which 11 are being conducted by YM and its four licensees. Three of the latter are Phase III trials, including one being conducted by the internationally recognized National Cancer Center of Singapore, which selected nimotuzumab over the alternative antibodies because of its benign side effect profile. Nimotuzumab is also available on a compassionate use basis in the US for children with pediatric glioma and is designated an Orphan Drug for adult and pediatric glioma by the FDA as well as the EMEA for Europe.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development. The Company is currently developing two late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM), and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
2. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
3. Neurocrine Biosciences Secures Committed Equity Financing Facility
4. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
5. Cell Biosciences Signs Agreement to Acquire Alpha Innotech
6. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
7. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
8. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
9. SABiosciences Ranked 17th on the Best Places to Work Industry Award for Biotech and Pharmaceutical Companies
10. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
11. Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  ECC West Africa, ... Colorado with University College Hospital (UCH) Ibadan ... development project to finance, design, construct, and operate and ... Nigeria . Under the first of the ... scoping documents and funding applications. UCH Ibadan intends to ...
(Date:7/24/2014)... materialise. Yet, scientists are making progress in devising ... such approach relies on quantum dotsa kind of ... field. A new study demonstrates that changing the ... with electrical impulses can help better control them. ... used as quantum information units, which would produce ...
(Date:7/24/2014)... , July 24, 2014 Research ... "Global Cell Culture Market 2014-2018" report to ... Cell culture is the in vitro growth ... as research, cell studies, and biopharmaceutical production. Cell culture ... production. Cell culture instruments and cell culture consumables are ...
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 /PRNewswire/ ... million, seven-year contract with the National Institute of Allergy ... of Health, to conduct preclinical development of potential therapies ... development of drugs to treat HIV and AIDS and ... as well as microbicides for preventing sexual transmission of ...
Breaking Biology Technology:ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... , EAST BRUNSWICK, N.J., Sept. 8 Savient ... abstracts relating to KRYSTEXXA(TM) (pegloticase) development and treatment failure gout will ... in Philadelphia from October 16-21, 2009. The posters will be ... and include: , , , ...
... , CAMBRIDGE, Massachusetts, September 8 ... the global specialty biopharmaceutical company, is,committed to doing everything ... imiglucerase supply shortage. Shire is pleased to be,able to ... previously,anticipated commercial launch world wide. , ...
... , SAN DIEGO, Sept. 8 Biomatrica, Inc., the ... key appointments that will expand the breadth of leadership and commercial ... continued rapid growth in the development and commercialization of products for ... , Martin Latterich, Ph.D., has joined the company ...
Cached Biology Technology:Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 2Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 3Multiple Abstracts Related to KRYSTEXXA(TM) Development and Treatment Failure Gout to be Presented at the 2009 ACR/ARHP Annual Scientific Meeting 4Update on velaglucerase alfa 2Update on velaglucerase alfa 3Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 2Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 3Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 4Biomatrica Makes Several Key Appointments as Part of Continued Growth Plan 5
(Date:7/25/2014)... the Terra satellite show the different areas that have been ... The burn scars show up as reddish-brown splotches of ... across the remote parts of Eastern Russia in the Sakha ... instrument, it is still possible to see the smoke ... noted below show the devastating number of fires that have ...
(Date:7/25/2014)... of biomedical engineering at the University of Houston, ... and artificial organ development., "Introduction to Tissue Engineering: ... entering into the field of artificial organ development. ... engineering at UH, served as a series editor ... are other published books on the subject of ...
(Date:7/25/2014)... (DTT), which is derived from diffusion tensor imaging ... tracts, such as the corticospinal tract, the rubrospinal ... corticospinal tract is known to be a major ... brain. Several studies have reported on injury of ... some studies have demonstrated recovery of a corticospinal ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2
... pressure were recently identified in a comprehensive international ... study, in which Uppsala University researchers participated, are ... Nature Genetics . High blood pressure ... Previous studies have shown that it is extremely ...
... May 8 Military and civilian personnel from the ... local homeland security, law enforcement and other first-responder personnel ... been encouraged to register and attend the 2009 Force ... held at Stafford Regional Airport and Marine Corps Base, ...
... and south sides of a house may decrease summertime ... a recent study* of California homes by researchers from ... the U.S. Department of Agriculture (USDA). The first ... the effects of shade on 460 single-family homes in ...
Cached Biology News:Comprehensive genetic study paves way for new blood-pressure medicines 2Demonstration Features Commercial Technology for Combating Terrorism 2New study: Home energy savings are made in the shade 2
Moue Serum 8-12 Weeks Old...
... is collected off the clot fasted non-Swiss Albino mice ... Available Anticoagulants: N-02: Citrate N-04: ... Potassium Oxalate N-10: EDTA (Na) ... CPD N-09: K3EDTA N-11: ...
Contains 100 positive controls for effective screening of HDAC inhibitors by fluorometric method....
dynactin 4, mRNA (cDNA clone MGC:3248 IMAGE:3505855), complete cds...
Biology Products: